See more : Koninklijke DSM N.V. (KDSKF) Income Statement Analysis – Financial Results
Complete financial analysis of Microbix Biosystems Inc. (MBXBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Microbix Biosystems Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Emergency Assistance Japan Co., Ltd. (6063.T) Income Statement Analysis – Financial Results
- Billington Holdings Plc (BILN.L) Income Statement Analysis – Financial Results
- Naturgy Energy Group, S.A. (GASNY) Income Statement Analysis – Financial Results
- Super Hi International Holding Ltd. (9658.HK) Income Statement Analysis – Financial Results
- NextEra Energy, Inc. Series N J (NEE-PN) Income Statement Analysis – Financial Results
Microbix Biosystems Inc. (MBXBF)
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.39M | 16.51M | 19.08M | 18.59M | 10.52M | 13.41M | 12.51M | 10.19M | 9.52M | 8.87M | 8.40M | 7.57M | 6.67M | 6.23M | 6.46M | 6.08M | 4.99M | 4.05M | 3.64M | 4.38M | 4.07M | 2.85M | 2.81M | 2.99M | 1.86M | 1.60M | 3.10M | 2.70M |
| Cost of Revenue | 10.00M | 9.03M | 7.95M | 7.55M | 5.86M | 6.86M | 7.14M | 5.37M | 4.54M | 3.03M | 3.89M | 3.74M | 3.91M | 3.24M | 2.73M | 2.52M | 2.48M | 2.12M | 1.75M | 1.68M | 1.49M | 1.02M | 835.27K | 949.84K | 577.27K | 600.00K | 600.00K | 500.00K |
| Gross Profit | 15.39M | 7.48M | 11.12M | 11.04M | 4.66M | 6.55M | 5.37M | 4.81M | 4.98M | 5.84M | 4.51M | 3.83M | 2.75M | 2.98M | 3.73M | 3.56M | 2.51M | 1.93M | 1.89M | 2.70M | 2.58M | 1.82M | 1.97M | 2.04M | 1.28M | 1.00M | 2.50M | 2.20M |
| Gross Profit Ratio | 60.61% | 45.30% | 58.32% | 59.40% | 44.28% | 48.82% | 42.92% | 47.25% | 52.33% | 65.81% | 53.73% | 50.62% | 41.30% | 47.92% | 57.78% | 58.60% | 50.36% | 47.74% | 51.94% | 61.72% | 63.36% | 64.03% | 70.24% | 68.22% | 68.91% | 62.50% | 80.65% | 81.48% |
| Research & Development | 2.13M | 2.05M | 1.80M | 1.03M | 1.01M | 1.04M | 1.09M | 994.58K | 493.61K | 1.28M | 691.07K | 445.82K | 560.00K | 530.07K | 494.25K | 703.06K | 1.19M | 985.42K | 886.05K | 572.87K | 966.80K | 668.39K | 443.78K | 346.67K | 228.62K | 3.80M | 1.60M | 900.00K |
| General & Administrative | 8.63M | 6.53M | 5.00M | 4.22M | 3.54M | 3.74M | 3.61M | 3.93M | 3.13M | 2.87M | 1.85M | 1.79M | 2.25M | 2.24M | 2.96M | 2.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 246.68K | 1.48M | 1.55M | 858.06K | 632.55K | 651.46K | 556.41K | 464.91K | 517.02K | 602.23K | 656.99K | 893.58K | 1.52M | 1.39M | 1.47M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.88M | 8.01M | 6.56M | 5.07M | 4.17M | 4.40M | 4.17M | 4.39M | 3.65M | 3.47M | 2.50M | 2.68M | 3.77M | 3.64M | 4.43M | 4.35M | 4.46M | 3.02M | 2.68M | 1.81M | 1.51M | 1.43M | 1.26M | 1.20M | 1.24M | 1.50M | 2.60M | 1.20M |
| Other Expenses | 482.14K | 161.24K | 160.34K | 99.40K | 0.00 | 0.00 | 0.00 | -273.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.49M | 10.22M | 8.51M | 6.21M | 5.19M | 5.44M | 5.26M | 5.39M | 4.14M | 4.75M | 3.19M | 3.09M | 4.33M | 4.63M | 5.39M | 5.93M | 6.00M | 4.27M | 3.81M | 2.55M | 2.63M | 2.25M | 1.86M | 1.73M | 1.67M | 5.60M | 4.50M | 2.30M |
| Cost & Expenses | 21.49M | 19.25M | 16.47M | 13.76M | 11.05M | 12.30M | 12.40M | 10.76M | 8.68M | 7.78M | 7.08M | 6.83M | 8.25M | 7.87M | 8.11M | 8.45M | 8.48M | 6.39M | 5.56M | 4.23M | 4.12M | 3.27M | 2.70M | 2.68M | 2.25M | 6.20M | 5.10M | 2.80M |
| Interest Income | 687.51K | 457.74K | 82.27K | 66.00 | 1.06M | 1.07M | 172.00 | 22.00 | 616.00 | 2.79K | 9.81K | 9.16K | 159.00 | 3.50K | 2.00K | 46.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 921.78K | 839.38K | 826.56K | 1.60M | 1.06M | 1.07M | 852.03K | 924.61K | 691.25K | 745.22K | 850.88K | 718.78K | 1.06M | 976.03K | 889.68K | 161.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.61M | 1.16M | 1.04M | 822.04K | 690.09K | 568.82K | 690.08K | 510.16K | 413.68K | 418.42K | 403.26K | 419.20K | 431.23K | 460.76K | 457.09K | 410.49K | 355.71K | 273.39K | 242.64K | 166.59K | 154.08K | 153.92K | 160.52K | 180.25K | 207.36K | 300.00K | 300.00K | 200.00K |
| EBITDA | 6.21M | 1.96M | 3.33M | 5.39M | -95.44K | 1.54M | -7.08M | -2.80M | 1.25M | 1.51M | 1.73M | 1.31M | -1.25M | -1.08M | -1.19M | -1.31M | -3.13M | -2.07M | -1.68M | 317.60K | 101.14K | -272.42K | 266.86K | 493.44K | -186.30K | -4.40M | -1.90M | 100.00K |
| EBITDA Ratio | 24.44% | 11.85% | 19.55% | 30.43% | 1.57% | 12.52% | 6.39% | -3.32% | 13.17% | 17.05% | 20.60% | 15.51% | -17.17% | -18.90% | -18.47% | -21.60% | -62.77% | -51.07% | -45.97% | 7.26% | 2.49% | -9.57% | 9.51% | 16.51% | -10.03% | -268.75% | -54.84% | 3.70% |
| Operating Income | 3.91M | -2.74M | 2.69M | 4.84M | -524.60K | 1.11M | -742.81K | -1.50M | 148.41K | 348.98K | 475.62K | 168.18K | -1.58M | -1.64M | -1.65M | -1.72M | -3.49M | -2.34M | -1.92M | 151.02K | -52.95K | -426.33K | 106.34K | 313.18K | -393.66K | -4.60M | -2.00M | -100.00K |
| Operating Income Ratio | 15.38% | -16.57% | 14.11% | 26.01% | -4.98% | 8.27% | -5.94% | -14.72% | 1.56% | 3.93% | 5.66% | 2.22% | -23.63% | -26.35% | -25.54% | -28.35% | -69.89% | -57.83% | -52.63% | 3.45% | -1.30% | -14.98% | 3.79% | 10.48% | -21.20% | -287.50% | -64.52% | -3.70% |
| Total Other Income/Expenses | -234.27K | 2.70M | -744.29K | -1.60M | -4.13M | -1.07M | -7.88M | -2.73M | -689.61K | -742.44K | -752.12K | 311.81K | -812.73K | -1.02M | -887.68K | 0.00 | 0.00 | -370.57K | -174.11K | 62.51K | 153.76K | 112.50K | 18.57K | 31.16K | 20.08K | 0.00 | 100.00K | 100.00K |
| Income Before Tax | 3.67M | -39.48K | 1.87M | 3.23M | -4.66M | 43.68K | -8.62M | -4.23M | 148.41K | 348.98K | 475.62K | 168.18K | -2.64M | -2.61M | -2.54M | 0.00 | 0.00 | -2.71M | -2.09M | 213.53K | 97.06K | -313.83K | 124.91K | 344.35K | -373.58K | 0.00 | -1.90M | 0.00 |
| Income Before Tax Ratio | 14.46% | -0.24% | 9.78% | 17.39% | -44.27% | 0.33% | -68.91% | -41.53% | 1.56% | 3.93% | 5.66% | 2.22% | -39.53% | -41.97% | -39.28% | 0.00% | 0.00% | -66.98% | -57.41% | 4.88% | 2.39% | -11.02% | 4.45% | 11.52% | -20.12% | 0.00% | -61.29% | 0.00% |
| Income Tax Expense | 150.56K | 0.00 | 77.23K | 1.60M | 1.57M | 11.76K | 852.03K | -450.00K | -600.00K | -265.00K | 306.65K | 166.80K | 159.00 | 3.50K | 887.68K | 759.98K | 177.83K | 0.00 | 211.61K | 88.00K | 82.79K | 49.88K | 55.40K | 103.23K | 76.65K | 100.00K | 200.00K | 100.00K |
| Net Income | 3.52M | -39.48K | 1.79M | 1.63M | -6.23M | 31.92K | -8.62M | -3.78M | 748.41K | 613.98K | 168.98K | 1.38K | -2.64M | -2.61M | -2.54M | -2.48M | -3.67M | -2.71M | -2.09M | 125.53K | 14.27K | -363.71K | 69.51K | 241.12K | -450.23K | -4.70M | -2.10M | -100.00K |
| Net Income Ratio | 13.86% | -0.24% | 9.38% | 8.77% | -59.17% | 0.24% | -68.91% | -37.11% | 7.86% | 6.92% | 2.01% | 0.02% | -39.53% | -41.97% | -39.28% | -40.85% | -73.45% | -66.98% | -57.41% | 2.87% | 0.35% | -12.78% | 2.48% | 8.07% | -24.25% | -293.75% | -67.74% | -3.70% |
| EPS | 0.00 | 0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 | 0.01 | 0.00 | 0.00 | -0.04 | -0.05 | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | -0.01 | -0.14 | -0.06 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 | 0.01 | 0.00 | 0.00 | -0.04 | -0.05 | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | -0.01 | -0.14 | -0.06 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 138.05M | 135.38M | 114.85M | 104.84M | 96.97M | 95.80M | 84.70M | 84.66M | 80.87M | 68.98M | 66.60M | 61.93M | 54.84M | 48.63M | 46.45M | 45.85M | 38.74M | 34.87M | 34.91M | 34.50M | 36.37M | 34.48M | 34.48M | 34.37M | 33.57M | 35.00M | 32.32M |
| Weighted Avg Shares Out (Dil) | 0.00 | 137.91M | 141.69M | 141.68M | 104.84M | 97.09M | 96.20M | 84.70M | 84.71M | 82.15M | 72.23M | 66.60M | 61.93M | 54.84M | 48.63M | 46.45M | 45.85M | 38.74M | 34.87M | 34.91M | 34.50M | 36.37M | 34.48M | 34.48M | 34.37M | 33.57M | 35.00M | 32.32M |
Microbix Biosystems Inc. (MBXBF) CEO Cameron Groome on Q2 2022 Results - Earnings Call Transcript
Microbix Biosystems Inc. (OTCQX:MBXBF) Q2 2022 Earnings Conference Call May 18, 2022 11:00 AM ET Company Participants Deborah Honig - IR, Adelaide Capital Cameron Groome - President and CEO Jim Currie - CFO Ken Hughes - COO Conference Call Participants...
Microbix Biosystems Inc. (MBXBF) CEO Cameron Groome on Q1 2022 Results - Earnings Call Transcript
Microbix Biosystems Inc. (MBXBF) CEO Cameron Groome on Q1 2022 Results - Earnings Call Transcript
Microbix Biosystems Inc. (MBXBF) CEO Cameron Groome on Q4 2021 Results - Earnings Call Transcript
Microbix Biosystems Inc. (MBXBF) CEO Cameron Groome on Q4 2021 Results - Earnings Call Transcript
Microbix Makes Early Repayment of 9% Interest Debenture
$1.3 million balance repaid, improving cash flow and resulting in non-cash charge $1.3 million balance repaid, improving cash flow and resulting in non-cash charge
Microbix Presenting Product Results at AACC
QAPs to Support Testing for COVID Viral Variants QAPs to Support Testing for COVID Viral Variants
Microbix Presenting at Muskoka Capital Conference
Meetings with Growth-Oriented Investors, September 24-26, 2021 Meetings with Growth-Oriented Investors, September 24-26, 2021
Microbix Biosystems' (MBXBF) CEO Cameron Groome on Q3 2021 Results - Earnings Call Transcript
Microbix Biosystems' (MBXBF) CEO Cameron Groome on Q3 2021 Results - Earnings Call Transcript
Microbix Reports Record Results for Q3 Fiscal 2021
Record Sales of $5.5 million, Record Net Earnings of $1.5 million Record Sales of $5.5 million, Record Net Earnings of $1.5 million
Microbix Upgrades U.S. OTC Market & Investor Relations
Trading Upgrade to OTCQX Best Market and Torrey Hills Capital Engaged Trading Upgrade to OTCQX Best Market and Torrey Hills Capital Engaged
OTC Markets Group Welcomes Microbix Biosystems Inc. to OTCQX
NEW YORK, Aug. 3, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announces that Microbix Biosystems Inc. (TSX: MBX; OTCQX: MBXBF) Microbix®, a Canadian life sciences company that creates,...
Source: https://incomestatements.info
Category: Stock Reports